South Korea Respiratory Drugs Market Size, Share, and COVID-19 Impact Analysis, By Disease Type (Asthma, Chronic Bronchitis, Chronic Obstructive Pulmonary Disease (COPD), Pleural Effusion, and Others), By Drug Class (Short-Acting Beta2-Agonists (SABA), Long-Acting Beta2-Agonists (LABA), Inhaled Corticosteroids (ICS), Anticholinergics, Antihistamines, Vasodilators, Combination Drugs, and Others), and South Korea Respiratory Drugs Market Insights, Industry Trend, Forecasts to 2035

South Korea Respiratory Drugs Market Size Insights Forecasts to 2035

• The South Korea Respiratory Drugs Market Size was estimated at USD 1.28 Billion in 2024
• The Market Size is Expected to Grow at a CAGR of around 8.99% from 2025 to 2035
• The South Korea Respiratory Drugs Market Size is Expected to Reach USD 3.3 Billion by 2035

According to a Research Report Published by Spherical Insights & Consulting, the South Korea Respiratory Drugs Market Size is anticipated to reach USD 3.3 billion by 2035, growing at a CAGR of 8.99% from 2025 to 2035. The Growth is driven by the increased incidence of COPD and asthma, particularly in the elderly population. The need for efficient respiratory treatments is also being accelerated by government-sponsored lung health programs, developments in inhalable biologics, and intelligent drug delivery systems.

Market Overview

The South Korea respiratory drugs market refers to the industry devoted to the creation, manufacturing, and distribution of pharmaceutical treatments for respiratory disorders like asthma, COPD, chronic bronchitis, and pleural effusion is known as the South Korean respiratory drugs market. Additionally, opportunities exist in the market because of the growing need for customized medication and the development of novel drug formulations. To create cutting-edge inhalation treatments that are customized to each patient's specific needs, regional pharmaceutical companies are spending money on research and development. Further, the expansion of digital health presents an opportunity to combine technology and respiratory care, giving patients access to remote monitoring and management tools. Biologics and biosimilars have been used more frequently recently to treat respiratory conditions, which suggests a shift to more advanced treatments. Moreover, a major factor in the expansion of the South Korean respiratory drugs market industry is the numerous programs and policies the government has put in place to enhance respiratory healthcare.

Report Coverage

This research report categorizes the market for the South Korea respiratory drugs market based on various segments and regions and forecasts revenue growth and analyses trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the South Korea respiratory drugs market. Recent market developments and competitive strategies such as expansion, product launch, and development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment of the South Korea respiratory drugs market.

Driving Factors

The rising incidence of respiratory conditions, especially asthma and chronic obstructive pulmonary disease (COPD), is driving a notable expansion in the South Korean respiratory drugs market. South Korea's Ministry of Health and Welfare estimates that 4 million consumers suffer from asthma, a 20% increase in the past ten years. Demand for efficient respiratory drugs is being driven by this expanding patient base. Reputable groups like the Korean Academy of Tuberculosis and Respiratory Diseases are essential for raising patient awareness and educating them, which highlights the market's need for cutting-edge treatments. Trends in healthcare investment aimed at enhancing respiratory healthcare services and drug availability show that the South Korean respiratory drugs market is on a promising growth trajectory, as an aging population and changing lifestyles are causing more respiratory ailments.

Restraining Factors

The market for respiratory drugs in South Korea is hampered by a number of important restraining factors, including high drug costs, restricted access in rural areas, regulatory delays, low patient adherence, and environmental concerns about inhaler emissions. These factors work together to prevent widespread adoption and slow innovation.

Market Segmentation

The South Korea respiratory drugs market share is classified into disease type and drug class.

• The asthma segment held a significant share in 2024 and is expected to grow at a significant CAGR during the forecast period.

The South Korea respiratory drugs market is segmented by disease into asthma, chronic bronchitis, chronic obstructive pulmonary disease (COPD), pleural effusion, and others. Among these, the asthma segment held a significant share in 2024 and is expected to grow at a significant CAGR during the forecast period. Get one of the most common respiratory conditions, asthma has a sizable patient base, which has led to significant research and medication development efforts to enhance management and treatment procedures.

• The combination drugs segment held a significant share in 2024 and is expected to grow at a significant CAGR during the forecast period.

The South Korea respiratory drugs market is segmented by drug class into short-acting beta2-agonists (SABA), long-acting beta2-agonists (LABA), inhaled corticosteroids (ICS), anticholinergics, antihistamines, vasodilators, combination drugs, and others. Among these, the combination drugs segment held a significant share in 2024 and is expected to grow at a significant CAGR during the forecast period. Combination medications are a major breakthrough because they streamline patient regimens by combining several therapeutic agents into one inhaler, improving compliance and treatment results.

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the South Korea respiratory drugs market along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

List of Key Companies

• Yuhan Corporation
• Hanmi Pharmaceutical
• Daewoong Pharmaceutical
• Boryung Pharmaceutical
• Chong Kun Dang Pharma
• Others

Recent Developments:

• In December 2022, Handok had signed a co-promotion agreement with Novartis Korea to launch and distribute three respiratory treatments Xoterna, Enerzair, and Atectura targeting COPD and asthma. These therapies included combination inhalers like ICS/LABA/LAMA, which offered improved lung function and symptom control.

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting and Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

Market Segment

This study forecasts revenue at South Korea, regional, and country levels from 2020 to 2035. Spherical Insights has segmented the South Korea Respiratory Drugs Market based on the below-mentioned segments:

South Korea Respiratory Drugs Market, By Disease Type

• Asthma
• Chronic Bronchitis
• Chronic Obstructive Pulmonary Disease (COPD)
• Pleural Effusion
• Others

South Korea Respiratory Drugs Market, By Drug Class

• Short-Acting Beta2-Agonists (SABA)
• Long-Acting Beta2-Agonists (LABA)
• Inhaled Corticosteroids (ICS)
• Anticholinergics
• Antihistamines
• Vasodilators
• Combination Drugs
• Others